167 related articles for article (PubMed ID: 28454366)
1. Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer.
Sun X; Wang X; Feng W; Guo H; Tang C; Lu Y; Xiang X; Bao Y
Oncol Lett; 2017 Apr; 13(4):2089-2096. PubMed ID: 28454366
[TBL] [Abstract][Full Text] [Related]
2. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
[TBL] [Abstract][Full Text] [Related]
3. Construction and Validation of an Oxaliplatin-Resistant Gene Signature in Colorectal Cancer Patients Who Underwent Chemotherapy.
Yin Y; Li S; Liang X; Li K; Xie M; Hu B
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145360
[TBL] [Abstract][Full Text] [Related]
4. ColoFinder: a prognostic 9-gene signature improves prognosis for 871 stage II and III colorectal cancer patients.
Shi M; He J
PeerJ; 2016; 4():e1804. PubMed ID: 26989635
[TBL] [Abstract][Full Text] [Related]
5. Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients.
Li J; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Deng Y
Cancer Manag Res; 2020; 12():3301-3310. PubMed ID: 32494194
[TBL] [Abstract][Full Text] [Related]
6. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
[TBL] [Abstract][Full Text] [Related]
7. Identification of Vitamin D-related gene signature to predict colorectal cancer prognosis.
Bu L; Huang F; Li M; Peng Y; Wang H; Zhang M; Peng L; Liu L; Zhao Q
PeerJ; 2021; 9():e11430. PubMed ID: 34035992
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
9. A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling.
Lin Q; Luo L; Wang H
Front Oncol; 2021; 11():644956. PubMed ID: 34026619
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Chang W; Gao X; Han Y; Du Y; Liu Q; Wang L; Tan X; Zhang Q; Liu Y; Zhu Y; Yu Y; Fan X; Zhang H; Zhou W; Wang J; Fu C; Cao G
Gut; 2014 Sep; 63(9):1457-67. PubMed ID: 24173294
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Zhuang L; Bai J; Huang H; Tang C; Yang J; Zhou B; Gong Y; Duanmu Z; Chen J
Oncol Res; 2010; 18(9):437-44. PubMed ID: 20524401
[TBL] [Abstract][Full Text] [Related]
12. DNA Repair-Related Gene Signature in Predicting Prognosis of Colorectal Cancer Patients.
Lv MY; Wang W; Zhong ME; Cai D; Fan D; Li CH; Kou WB; Huang ZP; Duan X; Hu C; Zhu Q; He X; Gao F
Front Genet; 2022; 13():872238. PubMed ID: 35495147
[No Abstract] [Full Text] [Related]
13. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.
Nguyen MN; Choi TG; Nguyen DT; Kim JH; Jo YH; Shahid M; Akter S; Aryal SN; Yoo JY; Ahn YJ; Cho KM; Lee JS; Choe W; Kang I; Ha J; Kim SS
Oncotarget; 2015 Oct; 6(31):31674-92. PubMed ID: 26397224
[TBL] [Abstract][Full Text] [Related]
14. Mitophagy-related gene signature predicts prognosis, immune infiltration and chemotherapy sensitivity in colorectal cancer.
Weng JS; Huang JP; Yu W; Xiao J; Lin F; Lin KN; Zang WD; Ye Y; Lin JP
World J Gastrointest Oncol; 2023 Mar; 15(3):546-561. PubMed ID: 37009318
[TBL] [Abstract][Full Text] [Related]
15. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
16. Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients.
Imai H; Saijo K; Komine K; Yoshida Y; Sasaki K; Suzuki A; Ouchi K; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
J Oncol; 2020; 2020():1701326. PubMed ID: 32655636
[TBL] [Abstract][Full Text] [Related]
17. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
Landre T; Maillard E; Taleb C; Ghebriou D; Guetz GD; Zelek L; Aparicio T
Int J Colorectal Dis; 2018 Aug; 33(8):1125-1130. PubMed ID: 29680896
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells.
Skarkova V; Kralova V; Krbal L; Matouskova P; Soukup J; Rudolf E
Exp Cell Res; 2018 Aug; 369(2):295-303. PubMed ID: 29842879
[TBL] [Abstract][Full Text] [Related]
19. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Cremolini C; Lonardi S; Bergamo F; Ning Y; Yamamoto N; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Stintzing S; Heinemann V; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2018 Sep; 18(5):623-632. PubMed ID: 29925895
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.
Díaz R; Aparicio J; Molina J; Palomar L; Giménez A; Ponce J; Segura A; Gómez-Codina J
Med Oncol; 2006; 23(3):347-57. PubMed ID: 17018892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
